A Budget Decision That Directly Touches Cancer Patients
Cancer treatment in India is often a race against both disease progression and financial exhaustion. For years, the cost of advanced cancer medicines has pushed families into debt, forced treatment discontinuation, or delayed therapy altogether. Against this backdrop, the Union Budget’s decision to remove basic customs duty on several high end cancer drugs is not just a fiscal move, but a healthcare intervention with real world consequences.
Customs Duty Waiver on Life Saving Cancer Drugs
The government has removed basic customs duty ranging from five to eleven percent on seventeen expensive medicines, many of which are essential in modern cancer care. These are largely imported drugs, and customs duty directly adds to their already high prices. By eliminating this tax, the government has acknowledged that life saving medicines should not be treated as luxury imports.
Which Cancer Drugs Become Cheaper
The duty exemption covers several widely used targeted and precision oncology drugs. These include Ribociclib, commonly prescribed in hormone receptor positive breast cancer, and Venetoclax, a critical drug for chronic lymphocytic leukemia and some acute leukemias. Ibrutinib, another cornerstone medicine in blood cancers, has also been included.
Targeted therapy drugs such as Dabrafenib and Trametinib, used in specific mutation driven cancers like melanoma, are part of the list. Ponatinib, a last line but life saving drug for resistant chronic myeloid leukemia, has also received duty relief. Liposomal Doxorubicin, often used when conventional chemotherapy causes severe toxicity, is another significant inclusion.
For many patients, these medicines are not optional add ons but the only effective treatment available.
Why This Matters More Than It Appears
Most of these drugs cost anywhere between two lakh to over fifteen lakh rupees per year. Even a ten percent reduction can translate into savings of tens of thousands of rupees annually. For patients on long term therapy, especially in metastatic cancers where treatment continues for years, this reduction can determine whether treatment is continued or stopped.
In a country where insurance penetration remains limited and out of pocket expenditure dominates healthcare spending, price sensitivity is not theoretical, it is existential.
A Long Overdue Correction in Cancer Drug Policy
India has made progress in producing generic medicines, but many newer cancer drugs remain under patent or are complex biologics. Until domestic manufacturing becomes viable, imports remain unavoidable. Taxing these imports effectively penalises patients for technological dependence.
Removing customs duty is a tacit admission that cancer drugs are essential public health goods, not revenue generating commodities. It also sends a signal that affordability must be factored into oncology policy, not left solely to market forces.
Relief for Patients, But Not the Final Answer
While this step is welcome, it does not fully address the broader crisis of cancer affordability in India. Drug prices remain high, access to diagnostics is uneven, and many patients still present late due to cost fears. Duty reduction should ideally be followed by stronger price negotiations, expansion of government funded cancer schemes, and faster approval of generics and biosimilars.
A Policy Move That Affects Lives, Not Just Numbers
Budget announcements often remain abstract for the public, but this decision will be felt directly in oncology clinics and hospital wards. For a patient being prescribed Ribociclib or Venetoclax, even a modest price reduction can mean one more cycle of treatment, one less loan, or one less compromise.
In a healthcare system where cancer too often becomes a financial death sentence before it becomes a medical one, this move offers limited but meaningful relief. The real test will be whether such patient centric decisions become the norm rather than the exception.
